Production of Highly Uniform Midbrain Organoids from Human Pluripotent Stem Cells

Author:

Yao Xuerui123,Kang Ji Hyun4,Kim Kee-Pyo5,Shin Hyogeun67,Jin Zhe-Long12,Guo Hao12,Xu Yong-Nan1,Li Ying-Hua1,Hali Sai8,Kwon Jeongwoo9,La Hyeonwoo10,Park Chanhyeok10,Kim Yong-June1112,Wang Lin3,Hong Kwonho10,Cao Qilong3,Cho Il-Joo67,Kim Nam-Hyung1234ORCID,Han Dong Wook1234ORCID

Affiliation:

1. Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China

2. International Healthcare Innovation Institute (Jiangmen), Jianghai, Jiangmen, Guangdong Province, China

3. Research and Development Department, Qingdao Haier Biotech Co. Ltd., Qingdao, China

4. Laboratory of Stem Cells and Organoids, OrganFactory Co. Ltd., Cheongju 28864, Republic of Korea

5. Department of Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea

6. Center for BioMicrosystems, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

7. Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Daejeon, Republic of Korea

8. Institute of Ophthalmology, University College London, London, UK

9. Primate Resources Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea

10. Department of Stem Cell and Regenerative Biotechnology, The Institute of Advanced Regenerative Science, Konkuk University, Seoul 05029, Republic of Korea

11. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea

12. Department of Urology, Chungbuk National University Hospital, Cheongju, Republic of Korea

Abstract

Brain organoids have been considered as an advanced platform for in vitro disease modeling and drug screening, but numerous roadblocks exist, such as lack of large-scale production technology and lengthy protocols with multiple manipulation steps, impeding the industrial translation of brain organoid technology. Here, we describe the high-speed and large-scale production of midbrain organoids using a high-throughput screening-compatible platform within 30 days. Micro midbrain organoids (µMOs) exhibit a highly uniform morphology and gene expression pattern with minimal variability. Notably, µMOs show dramatically accelerated maturation, resulting in the generation of functional µMOs within only 30 days of differentiation. Furthermore, individual µMOs display highly consistent responsiveness to neurotoxin, suggesting their usefulness as an in vitro high-throughput drug toxicity screening platform. Collectively, our data indicate that µMO technology could represent an advanced and robust platform for in vitro disease modeling and drug screening for human neuronal diseases.

Funder

Ministry of SMEs and Startups

Publisher

Hindawi Limited

Subject

Cell Biology,Molecular Biology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3